Drugs Made in America Acquisition CORP Form 4 insider transactions

Drugs Made In America Acquisition Corp. has amended its merger agreement with Power Analytics Global Corp, introducing changes to sponsor share treatment, rights offers, and potential for a three-party combination.

Drugs Made In America Acquisition Corp. has entered into a definitive merger agreement to acquire Power Analytics Global Corp. at a target enterprise valuation of $1 billion.

Drugs Made In America Acquisition LLC, a 10% owner and director, acquired 30,000 private units of Drugs Made In America Acquisition Corp. at $10 per unit on February 18, 2025.

Lynn Stockwell, Director, CEO, and Executive Chair of Drugs Made In America Acquisition Corp., reports acquiring 30,000 private units for $300,000, increasing her indirect holdings.

Drugs Made In America Acquisition LLC, a 10% owner of Drugs Made In America Acquisition Corp., reports transactions involving ordinary shares and rights to receive ordinary shares.

Lynn Stockwell, a director, 10% owner, CEO, and Executive COB of Drugs Made In America Acquisition Corp., reported the transfer and disposal of ordinary shares and rights to receive ordinary shares on January 29, 2025.

Myron W. Shulgan, a director of Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares from the Issuer's sponsor for no consideration on January 29, 2025.

Director Sridhar G. Prasad acquired 100,000 ordinary shares of Drugs Made In America Acquisition Corp. from the Issuer's sponsor for no consideration.

Catherine Do, a director of Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares from the company's sponsor for no consideration.

Glenn C. Worman, CFO of Drugs Made In America Acquisition Corp., acquired 100,000 ordinary shares from the company's sponsor on January 29, 2025.